INDV
Indivior Pharmaceuticals Inc · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 12:32 UTC
Last close
36.28USD
Market data, 2026-11-02
Except where said otherwise: 10-K for 2025, filed 2026-02-26
21.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
396.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
16.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
-7.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
n/aDividend yield
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
- Computed from the filing for 2016
Safety is the furthest below its sector's middle: 0.44 against 0.53 on the market's range.
- Growth13.9%82 of 100, above its sector
- Returns on capital396.9%98 of 100, above its sector
- Margins80.2%72 of 100, above its sector
- Price21.6x37 of 100, above its sector
- Safety0.7144 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aThe stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
Against its rival
lens 4 of 9Measure by measure
behind on 1 of 5- Profit on each unit of sales17.0%15.2%Ahead
Higher is better here.
- Return on the capital it uses397%17.1%Ahead
Higher is better here.
- Sales growth over five years13.9%35.4%Behind
Higher is better here.
- Debt against equityn/a0.57n/a
Lower is better here.
- Gross margin80.2%61.1%Ahead
Higher is better here.
- Price against earnings21.6x29.1xAhead
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Lantheus Holdings, Inc., INDV is behind on 1 of 5 measures.
Against Lantheus Holdings, Inc., INDV is behind on 1 of 5 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-26
Profit on each unit of sales16.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
Return on the capital it uses396.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
Sales growth over five years13.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
Gross margin80.2%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD
Price against earnings21.6x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001628280-26-012237
- Reported in
- USD